The stock of Edwards Lifesciences Corporation (NYSE:EW) increased by $1.12 on Monday to finish at $80.53, up 1.41 percent. The last five days have seen an average of 3,753,740 shares of common stock traded. 20 times new highs were reached in the current year, with a gain of $5.92. The average number of shares traded over the last 20 days was 3,681,040, while the average volume over the last 50 days totaled 3,065,432.
EW stock dropped -13.76% since last month. On 08/08/23, the company’s shares reached a one-month low of $77.16. The stock touched a high of $105.45 on 06/30/23, after rallying from a low of $67.13 in 52 weeks. The price of EW stock has risen by 7.93% or $5.92 this year, reaching a new high 20 times. Still, the stock price is down -23.63% from the 52-week high.
Insider Transactions
EW stock investors should be aware that Edwards Lifesciences Corporation (EW) stock had its last reported insider trading activity 1 day ago on Aug 14. On Aug 14, Global President TAVR & Surg Wood Larry L sold 6,421 shares at $79.30 each. This transaction resulted in the insider making $509,185. On Aug 14, BOBO DONALD E JR sold 4,500 shares at a price of US$79.30. After the transaction, the insider now owns 39,503 shares. Director STONE HEISZ LESLIE had earlier sold 3,303 shares on Aug 10 for $78.87 a share. The transaction was completed for $260,509.
Valuation Metrics
Edwards Lifesciences Corporation (EW) has a trailing price-to-earnings (P/E) ratio of 35.68. Beta for the stock is 1.02. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 8.53, the price-to-book (PB) ratio of 7.66, and the price-to-cash flow ratio of 70.76.
Financial Health
For the three months ended June 29, Edwards Lifesciences Corporation’s quick ratio was 2.30, while its current ratio was 3.20, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending June 29 is 0.09, and the total debt to equity ratio is 0.09. As far as profitability goes, gross margin for the trailing twelve months is 79.10% percent. Edwards Lifesciences Corporation’s EBITDA margin for the year ended June 29 was 34.73%, whereas its operating margin stood at 27.70% for the same period. Based on annual data, it had gross profit of $4.3 billion and revenue of $5.38 billion.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. EW’s return on assets (ROA) during the last 12 months has been 16.10%. There was a 23.50% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was 22.80%.
Earnings Surprise
According to Edwards Lifesciences Corporation’s quarterly financial report for the quarter that ended June 29, it had $596.7 million in total debt versus $466.7 million in cash and short-term investments. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $1.53 billion, while revenues rose by 10.21% to $1.46 billion. It was predicted that Edwards Lifesciences Corporation’s quarterly earnings would be $0.66, but it ended up being $0.65, beating the consensus by 1.50%. EBITDA was $363.3 million for the quarter. At the end of Edwards Lifesciences Corporation’s most recent quarter ended June 29, its liabilities totaled 2.56 billion, while its total debt was $684.5 million. Equity owned by shareholders amounts to $607.92 million.
Technical Picture
Here’s a quick look at Edwards Lifesciences Corporation’s (EW) price momentum from a technical perspective. As of 14 August, the RSI 9-day stood at 38.00%, suggesting the stock is Neutral, with a 18.10% historical volatility rate.
The stochastic %K and %D were 14.95% and 10.35% respectively, while the average true range (ATR) was 1.78. Based on the 14-day stochastic reading of 22.80%, the RSI (14) reading is 35.89%. On the 9-day MACD Oscillator, the stock is at 0.01, and the 14-day reading is at -1.79.
Analyst Ratings
In its analyst report released on July 19, 2023, Robert W. Baird began covering Edwards Lifesciences Corporation (NYSE: EW). The stock was rated as an Outperform by the brokerage firm. Analysts have assigned Edwards Lifesciences Corporation (EW) an Overweight rating. EW is a stock that is recommended for selling by 0 brokerage firms, while 13 companies recommend holding. The stock is underweighted by 1 analyst. Among the analysts who rate the stock, 3 rates it overweight and 13 others recommend it as a buy.
What is EW’s price target for the next 12 months?
The current consensus forecast for the stock is between $75.00 and $110.00, with a median target price of $99.00. In analyzing these forecasts, the average price target given by analysts for Edwards Lifesciences Corporation (EW) is $97.09.
